Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial
Sponsor: Novo Nordisk A/S
This PHASE2 trial investigates Non-alcoholic Steatohepatitis and is currently completed. Novo Nordisk A/S leads this study, which shows 43 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
43 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Completed PHASE2
▶ Show 38 earlier versions
-
May 2025 — Jun 2025 [monthly]
Completed PHASE2
-
Apr 2025 — May 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
May 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Ancona, Italy , Angers, France , Ankara, Turkey (Türkiye) , Ansan, South Korea , Arkhangelsk, Russia , Arlington, United States , Athens, Greece , Atlanta, United States , Baltimore, United States and 185 more locations